Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19

Taqi Hashmi F; Maysaa Ashkanani; Miaaz M Zidan; Lahoucine Naim; Afshan Hasan; Mohamed Nourelsabah Metwally

doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

2023, Vol: 7, Issue: 6

7 / 6Current Issue Online First Archive Aims and Scope Abstracting & Indexing Most Accessed Articles Most Downloaded Articles Most Cited Articles

Required files to be uploaded

Copyright Transfer Form

Original Research

Online Publishing Date:
26 / 12 / 2020

Int J Med Rev Case Rep. 2021; 5(2): 1-5

doi: 10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19

Taqi Hashmi F, Maysaa Ashkanani, Miaaz M Zidan, Lahoucine Naim, Afshan Hasan, Mohamed Nourelsabah Metwally.

Abstract
The study aim is to compare doxycycline (a tetracycline) versus placebo for the treatment of patients with suspected COVID19 caused by SARS-CoV-2 (a positive single-strand RNA virus) in an ultra-early timeframe starting at the time of presentation of a patient at primary health care centres prior to a confirmed PCR result and ending at day seven or two serial negative PCR results are found whichever is earlier. The aim is to abort viral replication, reduce morbidity and mortality, and reduce the R0 of infection transmission.
The following arguments support a biologically plausible use of tetracycline for the treatment of COVID19: (1) Metalloproteases (MMPs) are upregulated in human lung tissue in inflammatory lung disease (Greenlee et al. 2007), murine studies show increased expression of MMPs due to coronavirus infection (Zhou et al. 2005). Tetracyclines are known to chelate zinc from MMPs and inhibit MMP function (NYAS Publications ). (2) Tetracyclines inhibit the replication of positive single-strand RNA viruses such as the West Nile virus replication (Michaelis et al. 2007) and Dengue virus replication in tissue culture (Yang et al. 2007). (3) Doxycycline decreases the inflammatory cytokines such as IL-6, IL-1β, and TNF within 3 days reaching a peak effect at 7 days(Castro et al. 2011).

A doxycycline is therefore a treatment option that may be able to inhibit SARS-CoV-2 replication, morbidity and mortality and transmission.

Key words: COVID19, Doxycycline, Primary care, Treatment

	ARTICLE TOOLS
	Abstract
	PDF Fulltext
	How to cite this article
	Citation Tools
	Related Records
	Articles by Taqi Hashmi F Articles by Maysaa Ashkanani Articles by Miaaz M Zidan Articles by Lahoucine Naim Articles by Afshan Hasan Articles by Mohamed Nourelsabah Metwally
	on Google
	on Google Scholar

How to Cite this Article

Pubmed Style

F TH, Ashkanani M, Zidan MM, Naim L, Hasan A, Metwally MN. Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19. Int J Med Rev Case Rep. 2021; 5(2): 1-5. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

Web Style

F TH, Ashkanani M, Zidan MM, Naim L, Hasan A, Metwally MN. Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19. https://www.mdpub.net/?mno=1728 [Access: April 04, 2024]. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

AMA (American Medical Association) Style

F TH, Ashkanani M, Zidan MM, Naim L, Hasan A, Metwally MN. Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19. Int J Med Rev Case Rep. 2021; 5(2): 1-5. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

Vancouver/ICMJE Style

F TH, Ashkanani M, Zidan MM, Naim L, Hasan A, Metwally MN. Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19. Int J Med Rev Case Rep. (2021), [cited April 04, 2024]; 5(2): 1-5. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

Harvard Style

F, T. H., Ashkanani, . M., Zidan, . M. M., Naim, . L., Hasan, . A. & Metwally, . M. N. (2021) Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19. Int J Med Rev Case Rep, 5 (2), 1-5. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

Turabian Style

F, Taqi Hashmi, Maysaa Ashkanani, Miaaz M Zidan, Lahoucine Naim, Afshan Hasan, and Mohamed Nourelsabah Metwally. 2021. Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19. International Journal of Medical Reviews and Case Reports, 5 (2), 1-5. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

Chicago Style

F, Taqi Hashmi, Maysaa Ashkanani, Miaaz M Zidan, Lahoucine Naim, Afshan Hasan, and Mohamed Nourelsabah Metwally. "Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19." International Journal of Medical Reviews and Case Reports 5 (2021), 1-5. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

MLA (The Modern Language Association) Style

F, Taqi Hashmi, Maysaa Ashkanani, Miaaz M Zidan, Lahoucine Naim, Afshan Hasan, and Mohamed Nourelsabah Metwally. "Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19." International Journal of Medical Reviews and Case Reports 5.2 (2021), 1-5. Print. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

APA (American Psychological Association) Style

F, T. H., Ashkanani, . M., Zidan, . M. M., Naim, . L., Hasan, . A. & Metwally, . M. N. (2021) Doxycycline Ultra Early Treatment Trial (DUETT): A Randomized Controlled Trial Protocol for the Treatment of COVID-19. International Journal of Medical Reviews and Case Reports, 5 (2), 1-5. doi:10.5455/IJMRCR.Doxycycline-Ultra-Early-Treatment-Trial

About International Journal of Medical Reviews and Case Reports

International Journal of Medical Reviews and Case Reports (Int J Med Rev Case Rep)ISSN: 2534-9821The International Journal of Medical Reviews and Ca ... Read more.

For best results, please use Internet Explorer or Google Chrome.

Contact Information

Any correspondence, queries or additional requests for information on the manuscript submission process should be sent to the International Journal of Medical Reviews and Case Reports editorial office as follows:

Bulgarian Association of Young Surgeons (BAYS);

National Center of Public Health and Analyses (NCPHA), floor 2, office № 31, Sofia 1431, Bulgaria.

inkov@journalmedica.com

Financial department is managed by International Sci Ink Press.

It is a company registered in Bulgaria with registered no. 205414288 and registered address at 57 Antim I str., Vazrazhdane, Sofia, 1303, Bulgaria.

Tel: +359883427500

About International Journal of Medical Reviews and Case Reports

Contact Information

How to cite this article